Russell Investments Group Ltd. Has $959,000 Position in Takeda Pharmaceutical Co. $TAK

Key Points

• Russell Investments Group Ltd. increased its holdings in Takeda Pharmaceutical Co. by 42.2% during the first quarter, acquiring an additional 19,139 shares, raising their total to 64,463 shares valued at approximately $959,000.
• The stock has been downgraded from a "hold" rating to a "strong sell" by Zacks Research, with current consensus rates showing one Buy and one Sell evaluation.
• Despite the downgrades, Takeda reported an EPS of $0.52 for the last quarter, surpassing analysts' expectations of $0.47, although revenue fell short of estimates.

Russell Investments Group Ltd. lifted its stake in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 42.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,463 shares of the company's stock after acquiring an additional 19,139 shares during the period. Russell Investments Group Ltd.'s holdings in Takeda Pharmaceutical were worth $959,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. GAMMA Investing LLC boosted its position in shares of Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after purchasing an additional 1,296 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Takeda Pharmaceutical by 5.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company's stock worth $319,000 after purchasing an additional 1,098 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after purchasing an additional 1,045 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in shares of Takeda Pharmaceutical during the 1st quarter worth $262,000. Finally, Dimensional Fund Advisors LP increased its stake in Takeda Pharmaceutical by 60.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock worth $2,409,000 after purchasing an additional 68,200 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Takeda Pharmaceutical has a consensus rating of "Hold".

Takeda Pharmaceutical Stock Up 1.0%

Shares of TAK traded up $0.15 during midday trading on Thursday, reaching $15.30. 2,015,387 shares of the stock were exchanged, compared to its average volume of 2,858,481. The firm has a 50 day simple moving average of $14.82 and a 200-day simple moving average of $14.77. Takeda Pharmaceutical Co. has a 12-month low of $12.80 and a 12-month high of $15.56. The company has a market cap of $48.67 billion, a price-to-earnings ratio of 50.98 and a beta of 0.22. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The firm had revenue of $7.45 billion during the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.